Welcome to our dedicated page for Exagen SEC filings (Ticker: XGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company focused on autoimmune disease testing, and its SEC filings provide detailed information on this business. As a Delaware corporation with securities registered under Commission File Number 001-39049, Exagen submits periodic and current reports to the U.S. Securities and Exchange Commission that describe its financial condition, operations, and risks as a provider of autoimmune diagnostics and autoimmune testing solutions.
On this page, you can review Exagen’s SEC filings, including current reports on Form 8-K that furnish press releases about quarterly and year-to-date financial results. For example, the company has used Form 8-K to report results for periods ended June 30 and September 30, including revenue, operating loss, net loss, adjusted EBITDA, and balance sheet data such as cash and cash equivalents, borrowings, and warrant liabilities. These filings also include discussions of non-GAAP measures like adjusted EBITDA and explanations of how management uses these metrics.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the broader filing set) typically contain more extensive disclosures about Exagen’s autoimmune testing business, its AVISE-branded portfolio, regulatory and reimbursement considerations, and risk factors related to its operations and market. Proxy materials can provide additional detail on governance and equity compensation.
Stock Titan’s tools surface Exagen’s filings as they are posted to EDGAR and add AI-powered summaries that explain key points in accessible language. Investors can quickly locate 10-K and 10-Q reports for a deeper view of revenue trends and operating metrics, and track Form 8-K disclosures related to financial results. Where applicable, insider transaction reports on Form 4 can also be accessed to see equity activity by Exagen’s officers and directors.
Exagen Inc. reports a record 2025 revenue of $66.6 million, up about 19.7% from 2024, driven by higher testing volume and better pricing. The company’s flagship AVISE® CTD test generated 91% of revenue, underscoring its central role in the business.
Since launching an operational turnaround in 2022 under CEO John Aballi, Exagen has grown annual revenue by over 45%, expanded gross margin by more than 1,100 basis points, reduced operating expenses by over 20% and cut net loss by nearly 60%. AVISE CTD’s trailing twelve‑month average selling price reached $441 in 2025, about $30 higher than 2024, supported by payer engagement and new biomarkers.
The company focuses on autoimmune diagnostics for diseases such as lupus and rheumatoid arthritis, backed by proprietary technologies like its AVISE Lupus platform and T‑cell biomarkers. Management highlights pipeline programs in lupus nephritis, SLE and RA disease activity and states a belief that the business is positioned for continued revenue growth and positive Adjusted EBITDA over the next 12–18 months.
Exagen Inc. reported strong growth but ongoing losses for the quarter and year ended December 31, 2025. Full-year revenue reached $66.6 million, up 20% from 2024, with AVISE CTD test volume growing over 11% and average selling price rising to $441 per test.
Full-year gross margin improved to 58.3%, but the company posted a net loss of $19.9 million (or $0.93 per share), wider than 2024’s loss. Adjusted EBITDA was a loss of $9.8 million, slightly better than the prior year. Exagen ended 2025 with $32.2 million in cash and cash equivalents.
Management highlighted new biomarkers, sales-force expansion, and leadership additions, and noted a strengthened balance sheet following a $20 million stock offering and a $25 million credit facility. For 2026, Exagen expects revenue between $70 million and $73 million, signaling continued topline growth despite current unprofitability.
Exagen Inc. President and CEO John Aballi reported both a sale and a purchase of company stock. He sold 15,698 shares of common stock at an average price of
EXAGEN INC. reported an insider transaction by President and CEO John Aballi involving a mandatory share sale to cover taxes. On this Form 4, Aballi sold 11,430 shares of common stock at $3.61 per share, with the sale directed by the company solely to satisfy tax withholding obligations tied to vesting and settlement of restricted stock units. The filing states this was not a discretionary trade by Aballi. Following the transaction, he directly held 702,997 common shares, and there is an additional indirect holding of 40,401 shares reported as owned by his spouse.
EXAGEN INC. Chief Financial Officer Jeffrey G. Black reported an open-market sale of 1,584 shares of common stock at a price of
According to the footnote, the sale was carried out at the direction of the company solely to cover tax withholding obligations arising from the vesting and settlement of Restricted Stock Units. It is described as a mandated transaction rather than a discretionary sale by the executive.
Exagen Inc. investor RTW Investments, LP and Managing Partner Roderick Wong reported a 4.99% beneficial stake in the company’s common stock. They disclosed beneficial ownership of 1,148,768 shares, including warrants to purchase 358,306 shares, calculated against 22,663,099 shares outstanding as of October 31, 2025.
The warrants are subject to a 4.99% beneficial ownership limitation, preventing exercises that would push their stake above that level. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Exagen. Dividends and sale proceeds accrue to the RTW Funds advised by RTW Investments.
Exagen Inc. received an updated ownership filing from investment entities NMSIC Co-Investment Fund, L.P. and its general partner, Sun Mountain Capital Partners, L.L.C. The filing reports beneficial ownership of 1,368,958 shares of Exagen common stock, representing 6.04% of the outstanding shares, based on 22,663,099 shares outstanding as of October 31, 2025. The entities state that Sun Mountain, along with its controlling members Brian Birk and Sally Corning, may be deemed to share beneficial ownership of the shares held by NMSIC, while expressly disclaiming beneficial ownership beyond their direct holdings under applicable securities rules.
Jorey Chernett has filed a Schedule 13G reporting a significant ownership stake in Exagen Inc. The filing states beneficial ownership of 1,231,438 shares of Exagen common stock, representing about 5.4% of the class, with sole voting and dispositive power over all reported shares.
The filer certifies the securities were not acquired and are not held for the purpose of changing or influencing control of Exagen, and are not held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under the specified SEC rule.
Exagen Inc. filed a current report to share that it has issued a press release with select preliminary unaudited financial information for the three months and year ended December 31, 2025. The company explains that its financial closing procedures for this period are still in progress, so final results may differ from the preliminary figures described in the press release.
Exagen notes that its independent registered public accounting firm, BDO USA, P.C., has not audited, reviewed, compiled or applied procedures to the preliminary information and does not provide any assurance on it. The company states that the financial details under Item 2.02 are furnished rather than filed, while specific sections of the press release, including “Select Preliminary Unaudited 2025 Results,” “Cautionary Note Regarding Select Preliminary Unaudited Financial Results,” and “Forward Looking Statements,” are treated as filed under Item 8.01 and incorporated by reference.
Exagen Inc. reported Q3 2025 results showing stronger top-line performance and a larger loss. Revenue was $17.2 million, up from $12.5 million a year ago, with gross profit of $10.1 million. Operating loss narrowed to $3.1 million, but higher interest and a non-cash change in warrant liability drove a net loss of $7.1 million (vs. $5.0 million).
Cash and cash equivalents rose to $35.7 million as of September 30, 2025, supported by financing. The company completed a $18.6 million public offering in May and sold $3.4 million via its ATM. It also closed a $25.0 million initial draw under a new senior secured term loan with Perceptive, using $19.7 million to repay its 2017 loan; the facility permits draws up to $75.0 million subject to milestones. A warrant liability of $6.6 million was recorded, with a $2.7 million non-cash loss in the quarter.
Total assets were $62.8 million, liabilities $44.7 million, and stockholders’ equity $18.1 million. Shares outstanding were 22,663,099 as of October 31, 2025. A supplier agreement amendment adds minimum purchases aggregating $24.0 million through 2029. A previously disclosed qui tam matter was dismissed with prejudice on July 15, 2025.